from our files PROBUCOL ('Lorelco'; Dow)- A New Antihyperlipidaemic Rece ntly Introduced in the US Pharmacology Hy pocholeslerolemic effect of ".4' .(isopropyLidenedithio)-bis (2 ,6-<1i+ butylphenol)(probueoJ). Barnhart, J.W . tl at American Journal of

ainkaJ Nutritioo 2], 1229(! 9701. Endocrioeaod rnetaboJieindictsdurin, admiPistration ofa Lipophilic bi.~· phenol, proburol. Danowski. T.S. et aI. ainical Pbannaoology and

ThCnIpWtics 12: 929(1911). Modeofactiooofa DCW hypocholesttrolaem.ic drug (DH-5S I)in a familial hypen:hole:slcrotaemil. Miettinen, T. A. Alherosclemsis L5: 163 ( 19721. Sensitization to epil'lephrine-induced vertrh:ular fibrillation produced by prob\lCQI in 00gs. Marshall, N.N. a at TOJ:ic:ology and Applied PbarmawJogy 14: 594 (1973). Toxicity on4,4' -{i!Opropylidene-dilbio) bis U.6-di·\-oulylphcnoLl), probucol,

in mice. rats. dogs, and monkeys: dernollSlration ofa species· specific ph eoomo::no n. Moleno, J.A. et aI. Toxicology and Applied Pharmacology

24: 590([973). Probucot in the Iong·term treatment ofhyperdlOlesterolaemia. Pola(:hek. A. e! aI. CUrren! Medical Research and. Opinion I: J2J (1913). The additive effeclSof elofibra!eand probucol ( DH ·~81 jon rat serum choles!£'rol. DUDCan. C. H. el aI. Atherosclerosis 17: 161 (J 913). The additive effectof probuool on die! in hyperlipidemia. Brown. H.B. e! aI . ainica! PharmacoloaY and Therapeutics 16: 44 (1974). A n overview oflhe bioehemical pharmac:ologyofproburol. Barnhart. J .W. et aI . Lipids 12: 29( 1(77).

And th..-apeuttc use Biphellllbid (probucoll: a new hypoeboles!erolemic
Probucol - new dlOlesterol-lowering drug effective in paUeo1l; wilb type II byperlipoproteinemia. Salel. A.F. et aI . Clinic.a.l Pl\anrtaCOlogy and Thempeu\k:s 10, 690(]976).

INPHARMA 9th April. 1977 pl9